Bright Minds Biosciences Inc. DRUG
51.80
(1.71)
(3.20%)
as of 25 Sep
- Market cap
- $527.8M
- P/E
- 0.0×
Follow DRUG
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Dec '20 | Sep '20 | Sep '19 | Sep '17 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
36.10 | 11.33 | 24.25 | 8.11 | 31.38 | 31.38 | 31.38 | 2.18 | — |
Net Debt/EBITDA |
5.98 | 2.07 | 0.92 | 0.77 | 2.25 | 7.99 | 7.99 | 1.02 | — |
Debt/Assets |
0.05% | 0.65% | 0.00% | 0.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.71 | 0.66 | 0.95 | 0.91 | 0.85 | 0.00 | 0.03 | 0.53 | — |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (27.88%) | (45.96%) | (83.16%) | (99.25%) | (169.76%) | 93.93% | 190.38% | (18.59%) | — | |
| (26.97%) | (42.96%) | (75.07%) | (92.53%) | (43.17%) | (43.17%) | (85.66%) | (95.98%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(14.92%) | (51.33%) | (112.87%) | (142.85%) | (44.59%) | (44.59%) | (44.59%) | (181.76%) | — |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — | — |
Free Cash Flow per Share |
(0.90) | (0.32) | (1.40) | (4.31) | (3.23) | — | (0.17) | (0.02) | — |
Cash per Share |
8.62 | 0.98 | 1.35 | 3.69 | 8.71 | 0.00 | 12.21 | 0.05 | — |
Shareholders Equity per Share |
8.53 | 0.94 | 1.32 | 3.34 | 8.56 | 0.00 | 11.99 | 0.08 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
Book value per Share |
8.53 | 0.94 | 1.32 | 3.34 | 8.56 | 0.00 | 11.99 | 0.08 | — |
Free Cash Flow |
(6.21) | (1.36) | (5.21) | (10.64) | (5.79) | — | (0.22) | (0.03) | — |
Working Capital |
58.60 | 4.01 | 4.84 | 8.20 | 15.36 | 15.36 | 15.36 | 0.03 | — |
Net Current Asset Value |
58.57 | 3.98 | 4.84 | 8.15 | 15.36 | 15.36 | 15.36 | 0.03 | — |
| Other line items | |||||||||
Quick Ratio |
35.68 | 10.92 | 24.15 | 8.00 | 31.12 | 31.12 | 31.12 | 2.18 | — |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Cash ROIC |
(5.27%) | (16.38%) | (52.63%) | (61.09%) | (18.69%) | 0.00% | (0.69%) | (20.26%) | — |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | — | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
Operating CF per Share |
(0.90) | (0.32) | (1.40) | (4.31) | (3.23) | — | (0.17) | (0.02) | — |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — |
Average Receivables |
0.17 | 0.03 | 0.07 | 0.10 | 0.09 | 0.09 | — | — | — |
Average Payables |
0.97 | 0.24 | 0.63 | 0.80 | — | — | — | — | — |
Average Assets |
32.42 | 4.79 | 7.28 | 12.66 | 15.86 | 15.86 | 7.99 | 0.06 | — |
Average Common Equity |
31.36 | 4.48 | 6.57 | 11.81 | 4.03 | (7.29) | (3.60) | 0.32 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Columns are period end dates